Post-COVID Pulmonary Mucormycosis: first case report from Bangladesh | Zendy

Farhana Afroz | Zendy; Lovely Barai | Zendy; Muhammad Abdur Rahim | Zendy; Shamima Sharmin Kanta | Zendy; Md Delwar Hossain | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Post-COVID Pulmonary Mucormycosis: first case report from Bangladesh

Author(s) -

Farhana Afroz,

Lovely Barai,

Muhammad Abdur Rahim,

Shamima Sharmin Kanta,

Md Delwar Hossain

Publication year - 2021

Publication title -

bangladesh journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 2408-8366

pISSN - 1023-1986

DOI - 10.3329/bjm.v32i2.53802

Subject(s) - mucormycosis , medicine , diabetes mellitus , zygomycosis , amphotericin b , dermatology , lung , disease , intensive care medicine , antifungal , pathology , endocrinology

Mucormycosis is an invasive fungal infection caused by different saprophytic environmental fungus occurring predominantly among immunosuppressed patients. Pulmonary mucormycosis is the second most common form after rhino-cerebral mucormycosis and may accompany with other infections. Coronavirus disease 2019 (COVID-19) itself and its treatment with immunosuppressive drugs and oxygen delivery systems etc. are setting the scenes for opportunistic and co-infections with fungus and other pathogens. A middle aged Bangladeshi man, with background diabetes mellitus, hypertension, bronchial asthma and COVID-19, presented with fever, respiratory symptoms and cavitary lung lesion. Diagnostic work-up confirmed pulmonary mucormycosis and he responded with liposomal amphotericin B. To the best of our knowledge, this is the first case of post-COVID mucormycosis reported from Bangladesh. Bangladesh J Medicine July 2021; 32(2) : 156-160

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research